Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

INTRODUCTION: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we investigate resistance mechanisms to each drug alone, or to their combination u...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yen-Chao, Morrison, Gladys, Gillihan, Ryan, Guo, Jun, Ward, Robin M, Fu, Xiaoyong, Botero, Maria F, Healy, Nuala A, Hilsenbeck, Susan G, Phillips, Gail Lewis, Chamness, Gary C, Rimawi, Mothaffar F, Osborne, C Kent, Schiff, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326563/
https://www.ncbi.nlm.nih.gov/pubmed/22123186
http://dx.doi.org/10.1186/bcr3067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326563/
https://www.ncbi.nlm.nih.gov/pubmed/22123186
http://dx.doi.org/10.1186/bcr3067

Ejemplares similares